News and Events

June 17, 2009 --- AmProtein is proud to announce that it will be begin a Free Trial Offer of our Micro-bioreactor. Please contact us for more information or to request a free trial micro-bioreactor for your lab. Learn more about AmProtein's Mini- & Micro-bioreactors here.

May 22, 2009 --- AmProtein exhibited on the China Pavilion alongside its Chinese partners, North China Pharmaceutical Corporation's R&D Center and Harbin Pharmaceutical Group's Bioengineering Corporation, at this year's BIO International Convention. We showcased a working model of our US-spec 5L CURRENT Suspension & Perfusion Bioreactor system. The unit was well received generating much interest by both large and small laboratories for its versatility and performance. Read more about this our single-use bioreactor here.

April 15, 2009 --- GEN has published a corporate profile highlighting AmProtein's impressive disposable cell culture bioreactors and powerful expression systems. AmProtein's profile, "Firm on Quest to Improve Biomanufacturing," can be viewed here.

November 13, 2008 --- AmProtein has announced detailed data and specifications regarding the deveopment of it's most recent bioreactor, the CURRENT Perfusion Bioreactor System in an article entitled "A Single-use, Scalable Perfusion Bioreactor System." It can be downloaded here.

June 30, 2008 --- AmProtein will be presenting at WilBio"s 5th International Meeting (June 30th - July 2nd). The meeting will be held in Amsterdam and will focus on the "Development and Production of Antibodies, Vaccines, and Gene Vectors."

June 17, 2008 --- AmProtein will be exhibiting at BIO International Convention 2008 (June 17th - 20th). Look for us at booth number B6 (detail) on the California Pavilion! We will be launching our commercial CURRENT bioreactor line, expression system and novel bioreactors for vaccine production.

May 22, 2008 --- Updates concerning AmProtein's progress can be found in an article of the San Fernando Valley Business Journal article written on April 28, 2008. download.

May 20, 2008 --- AmProtein presented the new date of Amprotein expression technology in the PEGs conference held on April 28-May 2 2008 in Boston. If you are interested our presentation, please download.

April 28, 2008 --- AmProtein is sponsoring PEGS 2008 (April 28th - May 2nd) with a Luncheon Workshop, where Dr. Matthew Hui will be giving a presentation highlighting our recent advancements. AmProtein"s vector continues to achieve higher protein production speeds for both antibodies and recombinant proteins and our novel bioreactor line is nearing commercial launch. The luncheon will be held on Monday, April 28th at 12:40pm.

April 2, 2008 --- AmProtein gave a presentation at IBC's China 2008 Pharmaceutical R&D Summit on April 2nd in Shanghai. The presentation titled, "A Revolution in Generics and Enhanced Generics Production" highlighted the advantages of AmProtein"s proprietary protein production system for the production of biogenerics, a field that is projected to grow swiftly in the next 5 years.

January 28-29 2008 (Tokyo, Japan) --- AmProtein Corporation will be attending BioAsia Partnering Conference, Tokyo, Japan, January 28-29 2008 BIO-Asia 2008 - 2008 http://bioasia.bio.org/opencms/bioasia/2008/companies/index.jsp

January 7-11 2008 (San Diego, CA) --- AmProtein Corporation will be holding a workshop at http://www.chi-peptalk.com/08_PEX_day3.asp CHI's Peptalk 2008 January 7-11 2008 Wednesday, January 9 at Hotel Del Coronado, San Diego, CA AmProtein Corporation will be one of the sponsors for the CHI PepTalk 2008 at Hotel Del Coronado, San Diego, CA

A Revolution in Mammalian Gene Expression: Reaching Extremely High Protein & Antibody Expression (60-120pg/cell/day) in Three Weeks in Fast-Growing CHO Cells Matthew Hui, Ph.D., M.D., Founder & Chief Scientific Officer, AmProtein Corporation

AmProtein Corporation has just discovered a DNA structure-based common mechanism for possibly all eukaryotic gene expression. Based on this discovery, AmProtein has rapidly generated more than 10 cell lines, which produced more than 10 different proteins and antibodies at levels of 60-120pg/cell/day. All of these were achieved in three weeks in fast-growing CHO-KS cells after stable gene transfections. These results have strongly suggested that this discovery has revolutionized the protein production industry and made mammalian protein production rapid, affordable and dominant over other transgenic production methods. Currently, AmProtein is working on the more detailed mechanism and is applying this discovery to plant, yeast and insect gene expression.

October 8th 2007 (Los Angeles) --- Matthew Hui, another former Amgen scientist who left to form AmProtein in 2002, also hopes to tap Amgen's employee pool. He has only three employees now, but he hopes his new process for making mammalian cells that can more quickly produce the proteins used in biotech drugs will boost his Camarillo-based startup. More ...

October 2nd 2007 (Boston, MA) --- AmProtein is sponsoring a workshop at the BioProcess International Conference in Boston, MA on Tuesday, October 2nd. Dr. Matthew Hui, Founder and Chief Scientific Officer, will present 'A revolution in mammalian expression may reshape the future of research and biologics manufacture.' Meanwhile, Bioprocess International editors have asked AmProtein to prepare a manuscript of novel O2 transfer method for bioreactor design for their publication's February issue.

September 25th 2007 (Boston, MA) --- Dr. Hui will give a presentation entitled 'Reaching extremely high protein and antibody expression 30-80picograms/cell/day in three weeks in fast-growing CHO cells' on Tuesday, September 25th at the WilBio Cell Culture & Scale Up meeting in Boston. Also, AmProtein is currently working with 3 partners to further apply its mechanistic discovery for improving gene expression in all eukaryotic cells including insect, yeast, and plant.

September 9th 2007 (California) --- The Ventura County Star featured AmProtein in a story highlighting its recent discoveries on the front page of the Sunday Business section. Click here to read the article online. Furthermore, AmProtein is preparing a possible article for publication in Nature or Science entitled 'A DNA structure-based mechanism for Eukaryotic gene expression.' AmProtein is welcoming collaborators for this research and co-authorship.

August 1st 2007 (Singapore) --- Dr. Hui presented at WilBio's Asia/Pacific Regional meeting in Singapore, August 1st. His presentation was titled, 'Reaching 30-60 pg/cell/day in 2-3 weeks after only one stable gene transfection.'

July 8th 2007 (CAMARILLO, CA) --- AmProtein Corporation has discovered a novel mammalian expression vector that has achieved protein expression levels of 30 to 60 picograms per cell per day after only one stable gene transfection. This level of protein expression has never been achieved. The discovery of this proprietary vector has the potential to speed up drug development pipelines and reduce research costs dramatically. "The vector was constructed according to a common mechanism for high gene expression in eukaryotic cells", explains Chief Scientist, Matthew Hui, MD, PhD of AmProtein.
AmProtein has developed an effective non-bubbling oxygen transfer method for mammalian suspension culture bioreactors. This method is better than the sparging oxygen transfer method in that it is completely free of shear force, it rapidly maximizes dissolved oxygen, it avoids bubble burst-related cell damage, and it does not require the use of cell-toxic pure oxygen. Based on this novel oxygen transfer method, various types of single-use plastic bag bioreactors can be employed using ambient air as the gas supply. The AmProtein production system is ideal for high-density CHO cell suspension culture as well as for cell culture application to embryonic and adult stem cells. "This platform is scalable from bench to manufacturing and it makes current industrial bioreactors obsolete", said Dr. Hui. "The AmProtein discovery will impact the design of next-generation bioreactor systems beyond the pioneering work done by other single-use plastic bag-based bioreactors".
AmProtein has applied its expression system for the rapid production and subsequent development of dual-domain drug product candidates, the next intellectual property frontier in biologics. "By simply fusing two existing protein drugs together, we can create a new chemical entity capable of blocking two independent disease pathways," said Hui. "A new frontier in drug discovery has emerged". Using the ultra-efficient protein production platform, AmProtein has validated several dual domain protein drug candidates in small animal and nonhuman primate models. The dual domain drugs hold the promise of revolutionary therapies for cancer, cardiovascular disease, inflammation, and metabolic disease.

June 2007 --- AmProtein advertised its breakthrough discovery in mammalian gene expression in the scientific magazines, Nature Biotechnology (September and October), BioProcess International (Industry Yearbook, September, and the October supplement), Genetic Engineering News (September and October), and all of this year's remaining issues of China Biotechnology.

Feburary 2007 --- AmProtein issues a press release discussing its breakthrough in mammalian expression technology. To view a copy click here.